Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

JMP Securities Maintains Market Outperform on Crinetics Pharmaceuticals, Raises Price Target to $143

Author: Benzinga Newsdesk | September 26, 2025 07:11am
JMP Securities analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Market Outperform and raises the price target from $86 to $143.

Posted In: CRNX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist